Vancouver, British Columbia — August 4, 2026 — Leads & Copy — Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) has announced the grant of stock options to purchase up to 3,300,000 common shares of the Company, contingent on approval from the TSX Venture Exchange. The options are part of the Company’s stock option plan and are intended to reward the existing team and incentivize future contributions to Telo Genomics’ growth.
Of the total options granted, 2,500,000 were allocated to directors and officers, 600,000 to employees, and 200,000 to consultants. Each option will be exercisable at a price of $0.055 per share, with an expiry date of five years from the grant date. All options vest immediately upon being granted.
Options granted to directors, officers, and consultants, along with the underlying shares, will be subject to a four-month hold period, in adherence to the policies of the TSX Venture Exchange.
Telo Genomics is recognized as a biotechnology company at the forefront of developing a comprehensive telomere platform. This platform offers powerful applications and prognostic solutions, including liquid biopsies and related technologies, for the diagnosis and treatment of oncology and neurological diseases. The field of liquid biopsy is experiencing significant growth due to its less invasive nature and ease of replication compared to traditional diagnostic methods.
By integrating its team’s extensive expertise in the quantitative analysis of 3D telomeres with advances in molecular biology and artificial intelligence to identify disease-associated genetic instability, Telo Genomics aims to create simple and accurate products. These products are designed to improve patient care by addressing the needs of pathologists, clinicians, academic researchers, and drug developers.
The effectiveness of Telo Genomics’ proprietary technology has been supported by over 160 peer-reviewed publications and more than 30 clinical studies involving over 3,000 patients diagnosed with various cancers and Alzheimer’s disease. The Company’s lead application, Telo-MM, is currently under development to provide critical, actionable insights to medical professionals for the treatment of Multiple Myeloma, a severe form of blood cancer.
Source: Telo Genomics Corp.
